Upgrade to SI Premium - Free Trial

Lexicon Pharma (LXRX)

1.90 0.00 (0.00%)

Chart
Today 6M 1Y 5Y

Upcoming Events

- Earnings (7/30/26)

Latest Headlines

Form 4 LEXICON PHARMACEUTICALS, For: Jun 03 Filed by: Swain Judith L June 4, 2026 4:15 PM - SEC Filing Form 4 LEXICON PHARMACEUTICALS, For: Jun 03 Filed by: Sullivan Diane E. June 4, 2026 4:14 PM - SEC Filing Form 4 LEXICON PHARMACEUTICALS, For: Jun 03 Filed by: SOBECKI CHRISTOPHER J June 4, 2026 4:13 PM - SEC Filing Form 4 LEXICON PHARMACEUTICALS, For: Jun 03 Filed by: Cheung Ivan June 4, 2026 4:12 PM - SEC Filing Form 4 LEXICON PHARMACEUTICALS, For: Jun 03 Filed by: BARKER SAM L June 4, 2026 4:12 PM - SEC Filing Form 4 LEXICON PHARMACEUTICALS, For: Jun 03 Filed by: Amouyal Philippe June 4, 2026 4:11 PM - SEC Filing Form 4 LEXICON PHARMACEUTICALS, For: Jun 03 Filed by: DEBBANE RAYMOND June 4, 2026 4:10 PM - SEC Filing Lexicon to Present Data at the American Diabetes Association (ADA) 2026 Scientific Sessions June 3, 2026 8:00 AM - StreetInsider Lexicon Pharmaceuticals to Present at the 2026 Jefferies Global Healthcare Conference May 28, 2026 8:30 AM - StreetInsider Lexicon Pharmaceuticals to Present at the 4th Annual H.C. Wainwright BioConnect Investor Conference May 12, 2026 8:30 AM - Globe NewsWire Lexicon Pharmaceuticals (LXRX) PT Raised to $3.10 at Citi May 11, 2026 4:35 AM - StreetInsider Form 4 LEXICON PHARMACEUTICALS, For: Apr 30 Filed by: Artal Group S.A. May 8, 2026 9:45 PM - SEC Filing Form SCHEDULE 13D/A LEXICON PHARMACEUTICALS, Filed by: Invus Global Management, LLC May 8, 2026 9:43 PM - SEC Filing Form 10-Q LEXICON PHARMACEUTICALS, For: Mar 31 May 7, 2026 4:25 PM - SEC Filing Lexicon Pharma (LXRX) reported Q1 Revenue May 7, 2026 7:45 AM - StreetInsider Lexicon Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Clinical Updates May 7, 2026 7:35 AM - StreetInsider Form 8-K LEXICON PHARMACEUTICALS, For: May 07 May 7, 2026 7:32 AM - SEC Filing Lexicon Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Clinical Updates May 7, 2026 7:30 AM - Globe NewsWire Form 8-K LEXICON PHARMACEUTICALS, For: May 04 May 6, 2026 4:02 PM - SEC Filing Form 4 LEXICON PHARMACEUTICALS, For: May 01 Filed by: Amouyal Philippe May 4, 2026 4:59 PM - SEC Filing Form 4 LEXICON PHARMACEUTICALS, For: May 01 Filed by: SOBECKI CHRISTOPHER J May 4, 2026 4:57 PM - SEC Filing Form 4 LEXICON PHARMACEUTICALS, For: May 01 Filed by: BARKER SAM L May 4, 2026 4:33 PM - SEC Filing Form 4 LEXICON PHARMACEUTICALS, For: May 01 Filed by: Cheung Ivan May 4, 2026 4:30 PM - SEC Filing Form 4 LEXICON PHARMACEUTICALS, For: May 01 Filed by: Swain Judith L May 4, 2026 4:28 PM - SEC Filing Form 4 LEXICON PHARMACEUTICALS, For: May 01 Filed by: Sullivan Diane E. May 4, 2026 4:20 PM - SEC Filing Form 4 LEXICON PHARMACEUTICALS, For: May 01 Filed by: DEBBANE RAYMOND May 4, 2026 4:10 PM - SEC Filing Lexicon Pharmaceuticals secures $100 million loan facility with Hercules Capital May 4, 2026 4:06 PM - StreetInsider Lexicon Pharmaceuticals Announces $100 Million Loan Facility with Hercules Capital May 4, 2026 4:05 PM - StreetInsider Form 8-K LEXICON PHARMACEUTICALS, For: Apr 30 April 30, 2026 4:07 PM - SEC Filing Lexicon Pharmaceuticals to Report First Quarter 2026 Financial Results on May 7, 2026 April 30, 2026 8:00 AM - Globe NewsWire Lexicon to Present Data at the American Academy of Neurology (AAN) Annual Meeting April 17, 2026 8:00 AM - Globe NewsWire Lexicon Announces Three Presentations at the American College of Cardiology (ACC) Annual Scientific Session & Expo March 24, 2026 8:00 AM - Globe NewsWire Novo Nordisk begins phase 1 trial for oral obesity drug LX9851 March 23, 2026 7:30 AM - StreetInsider Lexicon Pharmaceuticals and Novo Nordisk Announce initiation of Phase 1 study with oral obesity drug candidate LX9851 March 23, 2026 7:30 AM - Globe NewsWire Form ARS LEXICON PHARMACEUTICALS, For: Dec 31 March 16, 2026 4:06 PM - SEC Filing Form DEFA14A LEXICON PHARMACEUTICALS, March 16, 2026 4:05 PM - SEC Filing Form DEF 14A LEXICON PHARMACEUTICALS, For: Mar 16 March 16, 2026 4:03 PM - SEC Filing H.C. Wainwright Reiterates Buy Rating on Lexicon Pharmaceuticals (LXRX): "significant upside potential exists" March 12, 2026 12:26 PM - StreetInsider Lexicon to Present Data on Effect of Kidney Function on the Long-term Efficacy and Safety of Sotagliflozin in Patients with Type 1 Diabetes at 19th International Conference on Advanced Technologies &a March 11, 2026 8:01 AM - Globe NewsWire Full Article List